In the late 1960s, University of Buffalo pathologist Richard Ablin announced that he had identified a substance secreted by prostate cells. The marker, which he termed prostate specific antigen (PSA), was elevated when those cells were diseased. The antigen could therefore be used to trace how a cancerous prostate was responding to treatment. Soon, Ablin's discovery was extended in a way that he vehemently disagreed with: that PSA would not only be used for monitoring treatment progress but also be used to screen for prostate disease. This discovery and the trend towards mass screening for prostate cancer is a critical waypoint in Helen Valier's A History of Prostate Cancer. Clinicians, patients and its manufacturers are massively enthusiastic about the PSA test. This has led, as Valier and the National Cancer Institute note, to a situation in which ‘despite a 3–4% lifetime risk of prostate cancer death, more than 17% of men in the US will be diagnosed with prostate cancer during their lifetime’ (p. 157). (That diagnosis rate is twice what it was forty years previously.) Of those diagnosed with the condition, 90 per cent will opt for treatment, and those are expensive treatments, as the book goes on to argue, often without a solid backing of evidence as to their efficacy, which also adversely affect patients’ quality of life. Prostate cancer, this book suggests, is an instance of urgency and financial interest in offering treatments overriding medical restraint.
In this recent addition to Palgrave Macmillan's Medicine and Biomedical Sciences in Modern History series, Valier takes on the ambitious task of writing a history of prostate cancer from ancient times through to the present day. Early chapters cover cancer in Greek and Islamic medicine, morbid anatomy and the emergence in the nineteenth century of prostate cancer as a distinct clinical entity. By the close of that century, prostate cancer was recognized as having two agreed features – that it is a common condition and that it is one associated with age. Valier here firmly sets her topic in context, drawing extensive connections with wider themes and events in medical history, sometimes at the cost of eclipsing prostate cancer in the narrative. There is an absorbing section on early twentieth-century thinking on sexual and moral hygiene and the healthy prostate gland, and a particularly tantalizing overview of physiologist Charles Huggins's work on the influence of sex hormones on prostate health. Huggins's investigations showed that reducing androgens by castration – chemical or otherwise – could improve a prostate cancer sufferer's symptoms. He won the Nobel Prize in Physiology or Medicine in 1966 for having demonstrated that not all cancers are ‘autonomous’ – that is, some cancers, such as prostate cancer, do respond to circulating hormones. Huggins's work opened the pathway for new non-surgical therapies. As Valier notes, this would be an excellent topic for deeper investigation.
The chapters dealing with developments post-1950 are where the weight of the book lies. In these chapters, Valier is particularly interested in tracing how certain research insights (such as Ablin's PSA marker) have been enthusiastically adopted by clinicians, companies and patients – all driving a considerable increase in rates of diagnosis. Further, Valier argues that enthusiasm for doing something about prostate cancer (and the fact that some treatments seem to offer self-evident benefits) has meant that a majority of men diagnosed with prostate cancer continue on to treatment. These interventions, the book shows, are not always supported by rigorous experimental data, in contradiction to the aims of modern evidence-based medicine.
In common with, for example, recent histories of cholesterol and diabetes, Valier notes that screening for prostate cancer has created patients who are not suffering from disease symptoms but who are, nevertheless, treated (‘pre-patients’). In this instance, the treatment is often drastic and beset with serious side effects of incontinence and sexual dysfunction. Further, she suggests that this zeal for seeking out and destroying prostate cancer has helped develop and support new treatments. In the case of, say, vastly expensive proton therapy, treatment facilities are only financially viable due the fact that large numbers of men seek treatment for prostate cancer – despite the fact that proton therapy has demonstrated efficacy only in other types of cancer.
Valier's focus is on researchers, institutions and companies, and from this evidence she argues that industry self-interest is what is driving the growing market for prostate cancer screening and treatment. Patient experience, patient activism and public health educational efforts are not within the scope of the book. These would certainly be important areas for future inquiry, and would add a useful dimension to Valier's investigation of the forces driving prostate cancer screening and treatment. This book-length treatment of prostate cancer is a much-needed addition to cancer history. Valier does a good job of indicating areas of interest and potential further inquiry in her important subject.
